#Paxlovid with zero benefit in those aged <65yo with #covid19 in new @NEJM retrospective case-control study of 109,254.
— David Boulware, MD MPH (@boulware_dr) August 24, 2022
Yes, a statistical benefit in >65yo (which is the headline), but no NNT mentioned. Cost might be $1/2Mil to prevent 1 hospitalization.https://t.co/m9DyGpMRJg
Study finds Pfizer COVID-19 pill had no benefit in middle-age adults
Paxlovid, the COVID-19 antiviral pill developed by Pfizer that was once celebrated as a "game-changer" for the pandemic
Paxlovid, the COVID-19 antiviral pill developed by Pfizer that was once celebrated as a "game-changer" for the pandemic, has little to no benefit for younger adults, while it still appears to reduce the risk of hospitalization or death for high-risk seniors, according to a new study published Wednesday.
“Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not,” the study published in the New England Journal of Medicine stated. "No evidence of benefit was found in younger adults."-- More...
Read next: Study Finds 64 Online Abortion Pill Vendors Violate FDA Safety Regulations
Email Us | Reader Friendly | Comments
The Blaze——Bio and Archives
Blaze Media is news and entertainment for people who love America. As one of the nation’s largest independent media companies, Blaze Media reaches over 165 million people each month through radio, podcasts, Roku, Amazon Fire, Apple TV, social media, email newsletters, and the web.
